Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Going off-label?

There’s a thin line between the legitimate and fraudulent 'off-label' promotion, as a recent US court case highlights

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

Who tops the pharma list?

Chris Ross, with the help of healthcare analysts GlobalData, takes a New Year look at the past, present and future of global pharma, and asks: what’s trending? 

- PMLiVE

Biocon plans February launch for first biosimilar Herceptin

Set to market own version of breast cancer drug in India

- PMLiVE

Boehringer switches diabetes candidate in Zealand collaboration

Will swap ZP2929 for another GLP-1 receptor agonist

Sanofi reception

Sanofi forms antibiotic research partnership

Will team up with Germany’s Fraunhofer-Gesellschaft to develop naturally-derived substances

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

- PMLiVE

Boehringer names new UK MD

Zinta Krumins has been with company for 25 years

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

- PMLiVE

Genzyme shocked by FDA’s rejection of Lemtrada

US regulator refuses to approve MS drug on safety grounds

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

Biogen Idec building

Biogen Idec licenses anti-TNF biosimilars

Treatment prospects emerge from joint venture with Samsung Biologics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links